Conference
A phase I study of various administration schedules for RO4929097 (R) with multi-parameter assessment (pharmacokinetics [PK] and primary tumor xenograft [XG]) in patients (pts) with advanced solid cancers.
Authors
Razak A; Bedard P; You B; Panchal D; Chen E; Hotte S
Volume
supp 1
Publisher
American Association for Cancer Research
Conference proceedings
Molecular Cancer Therapeutics
Issue
10
ISSN
1535-7163